Ozurdex is now available in China for the treatment of adult patients with macular edema secondary to retinal vein occlusion, Allergan announced in a press release.
Ozurdex (dexamethasone intravitreal implant 0.7 mg) was approved in October 2017 and is the first intravitreal injection approved for RVO in China.
“RVO is a devastating condition that affects millions of patients in China. ... Being able to offer these patients a proven treatment option allows ophthalmologists to consider a more tailored management approach, helping to reduce the treatment burden for patients and alleviate
Uncategorized